The Change of NK Cell Activity After Head and Neck Cancer Surgery
NCT02661776 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29
Last updated 2017-10-02
Summary
Cellular immunity can be changed after surgery and anesthesia. Tissue injury by surgical procedures significantly reduces the immune function in proportion to the degree of tissue injury. In addition, the use of opioids as analgesics during the perioperative period depress cellular immunity, in particular the activity of the natural killer (NK) cells. This perioperative immunosuppression may cause deleterious consequences on postoperative outcome in cancer patients. The aim of this study is to confirm the presence or extent of the change of NK cell activity between before and after head and neck surgery. Additionally, investigators will identify the clinical or genetic factors related to the change of NK cell activity.
Conditions
- The Patients Undergoing Head and Neck Surgery Including Tumor Removal and Reconstruction With Flap
Sponsors & Collaborators
-
Yonsei University
lead OTHER
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-03-24
- Primary Completion
- 2017-05-04
- Completion
- 2017-05-04
Countries
- South Korea
Study Locations
More Related Trials
-
NK Cells Infusion for Advanced Malignancies
NCT03619954 ·Status: UNKNOWN ·Phase: PHASE1
-
The Effects of Upper Airway and Digestive Tract Tumors on the Immune System
NCT00001603 ·Status: COMPLETED
-
Natural Killer Cells Reconstitution Kinetics Post Haploidentical Transplantation
NCT02978274 ·Status: UNKNOWN
-
Immune Response in Cervical Lymph Nodes of Patients With Head and Neck Cancer
NCT07131566 ·Status: RECRUITING
-
Study of Blood Immune Cells in Cancer Patients Compared to Controls
NCT01312701 ·Status: UNKNOWN
-
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
NCT04550663 ·Status: UNKNOWN ·Phase: PHASE1
-
The Role of Regulatory T Cell in Ovarian Cancer: Focus on Relationship Between Clinical Prognosis and Regulatory T Cell Expression
NCT00854282 ·Status: UNKNOWN ·Phase: NA
-
Cellular Immunity and Renal Cell Cancer
NCT04377113 ·Status: COMPLETED
-
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
NCT00823524 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Influenza Vaccination in Cancer Patients
NCT02213432 ·Status: TERMINATED ·Phase: NA
-
NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
NCT05528341 ·Status: RECRUITING ·Phase: PHASE1
-
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
NCT05131763 ·Status: UNKNOWN ·Phase: PHASE1
-
Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients
NCT04910295 ·Status: COMPLETED
-
Serum Immunological Profiles in Head and Neck Cancer Patients Receiving Curative Radiotherapy
NCT03325036 ·Status: COMPLETED
-
Study of Polyfunctionality of Anti-tumor T Lymphocytes in Cancerology: Potential Biomarker for Emerging Immunotherapies
NCT02880046 ·Status: UNKNOWN
-
Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection
NCT00521287 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor
NCT02562963 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
NCT05976906 ·Status: UNKNOWN ·Phase: PHASE1
-
NK Cells Treatment for COVID-19
NCT04280224 ·Status: COMPLETED ·Phase: PHASE1
-
microRNA Profile in Umbilical Cord Blood NK Cells
NCT00751569 ·Status: UNKNOWN
-
A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study
NCT05394714 ·Status: RECRUITING ·Phase: PHASE1
-
Vaccine Response With NT-I7
NCT04054752 ·Status: WITHDRAWN ·Phase: PHASE1
-
Cytokine Regulation of Natural Killer Receptors in Inhibiting Activated T Cell Function
NCT00173290 ·Status: UNKNOWN
-
Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History
NCT06821685 ·Status: RECRUITING ·Phase: PHASE1
-
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors
NCT06509490 ·Status: RECRUITING ·Phase: NA